Date:9/24/2009

ctivities (7,843,281) (4,670,844) Cash flows from financing activities: Issuance of preferred stock -- 13,248,054 Dividends paid (73,944) (83,206) Repayment of short-term bank loans -- (826,140) Treasury stock (111,587) -- Repayment of shareholder loans -- (146,143) Repayment of long-term bank loans -- (119,667) Net cash provided by (used in) financing activities (185,531) 12,072,898 Effect of foreign currency translation on cash (13,113) 321,789 Net increase in cash and cash equivalents 295,073 11,432,760 Cash and cash equivalents at beginning of year 12,057,150 624,390 Cash and cash equivalents at end of year $12,352,223 $12,057,150
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
5. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
6. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
7. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
8. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
9. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
10. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
11. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders